Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis ...

In a groundbreaking new study, the active ingredient in Ozempic was found to be so effective at treating arthritis that ...

For individuals with obesity and knee osteoarthritis, once-weekly semaglutide yields greater reductions in body weight and ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...